| Ol (lots) | Call Price | Strike Price | Put Price | Ol (lots) |
|---|---|---|---|---|
| - | - | 4,400 | ₹3 0% | 2,5000% |
| - | - | 4,450 | ₹17.75 0% | 5000% |
| - | - | 4,500 | ₹3.95 -23.3% | 8,875-1.38% |
| - | - | 4,550 | ₹19 0% | 1250% |
| 2500% | ₹991.6 0% | 4,600 | ₹18 0% | 1250% |
| - | - | 4,800 | ₹7.5 0% | 6,7500% |
| - | - | 4,850 | ₹19.25 0.26% | 1,3750% |
| - | - | 4,950 | ₹44.1 0% | 3750% |
| 6250% | ₹594.2 0% | 5,000 | ₹15.5 -13.4% | 8,500-1.44% |
| - | - | 5,050 | ₹59.7 0% | 1,2500% |
| 1,1250% | ₹512.75 0% | 5,100 | ₹22.05 -7.74% | 6,5000% |
| - | - | 5,150 | ₹45.8 0% | 2500% |
| 7500% | ₹294.15 0% | 5,200 | ₹34.65 -15.59% | 23,8752.13% |
| - | - | 5,250 | ₹44.85 -14.65% | 9,2500% |
| 7,7500% | ₹299.75 0% | 5,300 | ₹48.7 -12.8% | 13,8750% |
| 3,6250% | ₹310.3 0% | 5,350 | ₹74.65 0% | 10,1250% |
| 27,750-0.44% | ₹243.1 6.85% | 5,400 | ₹73.2 -14.18% | 25,7502.48% |
| 2,7500% | ₹203 0% | 5,450 | ₹110.75 9.27% | 3,0000% |
| 16,125-7.19% | ₹184.9 3.99% | 5,500 | ₹113.2 -3.41% | 32,500-1.51% |
| 3,3758% | ₹165.3 11.31% | 5,550 | ₹132.8 -3.38% | 1,50020% |
| 29,2502.63% | ₹135.5 8.7% | 5,600 | ₹154.7 -9.05% | 4,00010.34% |
| 1,7500% | ₹109.4 4.83% | 5,650 | - | - |
| 16,1252.38% | ₹92.15 8.66% | 5,700 | - | - |
| 00% | ₹34.2 0% | 5,750 | - | - |
| 29,1251.74% | ₹62 8.29% | 5,800 | ₹399.6 0% | 2500% |
| 2,6250% | ₹42.6 -0.23% | 5,850 | - | - |
| 29,0004.03% | ₹42.35 21.17% | 5,900 | - | - |
| 25,7500% | ₹27.8 0.72% | 5,950 | - | - |
| 27,0000.46% | ₹26 19.26% | 6,000 | ₹420 0% | 5000% |
| 1,8750% | ₹11 0% | 6,050 | - | - |
| 9,000-2.70% | ₹15 21.95% | 6,100 | - | - |
| 2500% | ₹14.55 123.84% | 6,150 | - | - |
| 7,125-8.06% | ₹9.65 12.2% | 6,200 | ₹518.2 0% | 00% |
| 1,37522.22% | ₹6.5 10.16% | 6,300 | - | - |
| 2,2500% | ₹8 0% | 6,400 | - | - |
This inspection, conducted from March 10 through March 13, 2025, was to evaluate compliance with the legal standards concerning bioequivalence studies.
The company saw its revenues increase by 1.5% YoY at ₹3,374 crore from ₹3,324 crore.
The serum contains liposomal azelaic acid, liposomal 4-butyl resorcinol, tranexamic acid, alpha arbutin, and niacinamide.
R&D expenses rose to ₹146.5 crore, making up 4.3% of total revenue, compared to ₹115.8 crore (3.4% of revenue) in the previous year.
This comes after competing private equity firms TPG Capital, Apax Partners, and KKR withdrew their original interest.
Alkem will conduct clinical trials of 'SON-080' in India, with Sonnet's support for global and local regulatory submissions.
According to sources, the floor price would be ₹5,616 per share, which is 3% lower than the current market price (CMP).
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Reg. No. INM000010940, SEBI RA Regn. No: INH000000248, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
